fx-322 hearing loss treatment

Frequency Therapeutics Expands Clinical Development Team with Appointment of Jeffery T. Lichtenhan, Ph.D.

LEXINGTON, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced the expansion of its clinical development team with the addition of Jeffery T. Lichtenhan, Ph.D., a leading expert in hearing diagnostics…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Releases New Data from Two FX-322 Clinical Studies; Plans to Advance Single-Dose Regimen

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), today announced topline, day-90 data from its FX-322 Phase 2a study (FX-322-202). The interim results show that four weekly injections in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. No treatment-related serious adverse events were observed…

Read More
frequency therapeutics student grant

Frequency Therapeutics Sponsors Student Education at Future of Hearing Healthcare Conference

Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced its sponsorship of the Future of Hearing Healthcare Conference, which will allow 55 audiology graduate students to attend the event at no cost. The…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Announces Publication of Phase 1/2 Data of FX-322 in Acquired Sensorineural Hearing Loss

WOBURN, MASSACHUSSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced the publication of its FX-322 Phase 1/2 study results in Otology & Neurotology, a leading peer reviewed journal focused on…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Appoints Kevin Franck, Ph.D., as Senior Vice President, Strategic Marketing and New Product Planning

WOBURN, MASSACHUSSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical stage biotechnology company focused on harnessing the body’s innate biology to repair or  reverse damage caused by a broad range of degenerative diseases, today announced the appointment of Kevin Franck, Ph.D., as Senior Vice President of Strategic Marketing and New  Product Planning. Dr. Franck will…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Provides Business Updates and Q3 2020 Financial Results

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the third quarter ended September 30, 2020. The company has continued to advance the clinical…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Expands FX-322 Clinical Development Program; Announces Upcoming Day-90 Phase 2a Analysis

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today provided an update to its strategy and clinical development program for FX-322, its lead product candidate for the treatment of acquired sensorineural…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Completes Enrollment of FX-322 Phase 2a Study for Sensorineural Hearing Loss

WOBURN, MASSACHUSSETTS — Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, has announced the completion of enrollment of its Phase 2a study of FX-322 for sensorineural hearing loss (SNHL). The company anticipates obtaining full…

Read More
fx-322 hearing loss treatment

Frequency Therapeutics Finds Sustained Improvement in Hearing Loss Patients Treated with FX-322

WOBURN, MASSACHUSETTS – Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today presented clinical results from a longer-term durability study of FX-322, showing that some patients with chronic sensorineural hearing loss had significant improvement…

Read More
frequency therapeutics fx 322 hearing loss drug

Frequency Therapeutics Provides Business Updates and Reports Q2 2020 Financial Results

WOBURN, MASSACHUSSETTS — Frequency Therapeutics,  a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced business updates and financial results for the second quarter ended June 30, 2020. “We are pleased with the steady progress in our Phase 2a…

Read More